AML
News
Chemo for solid tumors and risk of tMDS/AML
Chemotherapy for solid tumors is associated with an increased risk of therapy-related myelodysplastic syndromes or acute myeloid leukemia (tMDS/...
From the Journals
Higher AML, MDS risk linked to solid tumor chemotherapy
Most tMDS/AML cases expected to occur within the next 5 years will be attributable to chemotherapy, the researchers reported.
Conference Coverage
Quizartinib improves survival of FLT3-mutated AML
SAN DIEGO – QuANTUM-R is the first randomized trial to show a survival benefit over salvage chemotherapy in patients with FLT3-ITD mutated AML.
News
FDA approves first treatment for BPDCN
The U.S.
Conference Coverage
NCI director: Data failures cost lives
SAN DIEGO – Too many patients die because numbers aren’t aggregated or shared, Dr. Ned Sharpless said at the ASH meeting.
News
Algorithm uncovers DS in AML patients on IDH inhibitors
SAN DIEGO—An algorithm has proven effective for identifying differentiation syndrome (DS) in patients taking ivosidenib or enasidenib, according...
Conference Coverage
In IDH-mutated AML, first-line IDH inhibitors plus chemo may boost remission
SAN DIEGO – Minimal residual disease and mutational clearance were seen in a significant proportion of patients.
Video
FLT3 inhibitor moves forward in newly diagnosed AML
SAN DIEGO – Dr. Keith W. Pratz reviewed results from a phase 1 study of gilteritinib and next steps in newly diagnosed patients.
Video
Model bests IPSS-R for predicting survival, risk for AML in myelodysplastic syndrome
Video
Beat AML trial delivers genomic results in 7 days
SAN DIEGO – The umbrella trial, sponsored by the Leukemia & Lymphoma Society, harnesses technology to speed genomic results that could...
News
FDA warns of serious side effect of AML treatment
Differentiation syndrome may be overlooked in AML patients taking enasidenib (Idhifa).